# Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

> **NCT05539365** · PHASE2 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Unresectable Triple-Negative Breast Carcinoma

## Interventions

- **BIOLOGICAL:** Alpha-type-1 Polarized Dendritic Cells
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Leukapheresis
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT05539365
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-02-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never activated.
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05539365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05539365, "Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05539365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*